This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vatolin, S. Articles by Lobanenkov, V. V. Search for Related Content PubMed PubMed Citation Articles by Vatolin, S. Articles by Lobanenkov, V. V.

Conditional Expression of the CTCF-Paralogous Transcriptional Factor BORIS in Normal Cells Results in Demethylation and Derepression of MAGE-A1 and Reactivation of Other Cancer-Testis Genes

¹ Laboratory of Immunopathology, National Institutes of Allergy and Infectious Disease, ² Laboratory of Biosystems and Cancer, and ³ Thoracic Oncology Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: Victor V. Lobanenkov, Molecular Pathology Section, Laboratory of Immunopathology, National Institutes of Allergy and Infectious Disease, NIH, Twinbrook I, Room 1417, MSC-8152, 5640 Fishers Lane, Rockville, MD 20852. Phone: 301-435-1690; Fax: 301-402-0077; E-mail: vlobanenkov{at}niaid.nih.gov.

Brother of the Regulator of Imprinted Sites (BORIS) is a mammalian CTCF paralog with the same central 11Zn fingers (11ZF) that mediate specific interactions with varying 50-bp target sites. Regulated in vivo occupancy of such sites may yield structurally and functionally distinct CTCF/DNA complexes involved in various aspects of gene regulation, including epigenetic control of gene imprinting and X chromosome inactivation. The latter functions are mediated by meCpG-sensitive 11ZF binding. Because CTCF is normally present in all somatic cells, whereas BORIS is active only in CTCF- and 5-methylcytosine–deficient adult male germ cells, switching DNA occupancy from CTCF to BORIS was suggested to regulate site specificity and timing of epigenetic reprogramming. In addition to 11ZF-binding paternal imprinting control regions, cancer-testis gene promoters also undergo remethylation during CTCF/BORIS switching in germ cells. Only promoters of cancer testis genes are normally silenced in all somatic cells but activated during spermatogenesis when demethylated in BORIS-positive germ cells and are found aberrantly derepressed in various tumors. We show here that BORIS is also expressed in multiple cancers and is thus itself a cancer-testis gene and that conditional expression of BORIS in normal fibroblasts activates cancer-testis genes selectively. We tested if replacement of CTCF by BORIS on regulatory DNA occurs in vivo on activation of a prototype cancer-testis gene, MAGE-A1. Transition from a hypermethylated/silenced to a hypomethylated/activated status induced in normal cells by 5-aza-2'-deoxycytidine (5-azadC) was mimicked by conditional input of BORIS and is associated with complete switching from CTCF to BORIS occupancy at a single 11ZF target. This site manifested a novel type of CTCF/BORIS 11ZF binding insensitive to CpG methylation. Whereas 5-azadC induction of BORIS takes only few hours, derepression of MAGE-A1 occurred 1 to 2 days later, suggesting that BORIS mediates cancer-testis gene activation by 5-azadC. Indeed, infection of normal fibroblasts with anti-BORIS short hairpin RNA retroviruses before treatment with 5-azadC blocked reactivation of MAGE-A1. We suggest that BORIS is likely tethering epigenetic machinery to a novel class of CTCF/BORIS 11ZF target sequences that mediate induction of cancer-testis genes.

This article has been cited by other articles:

				L.-B. Wan, H. Pan, S. Hannenhalli, Y. Cheng, J. Ma, A. Fedoriw, V. Lobanenkov, K. E. Latham, R. M. Schultz, and M. S. Bartolomei Maternal depletion of CTCF reveals multiple functions during oocyte and preimplantation embryo development Development, August 15, 2008; 135(16): 2729 - 2738. [Abstract] [Full Text] [PDF]

				P. Nguyen, H. Cui, K. S. Bisht, L. Sun, K. Patel, R. S. Lee, H. Kugoh, M. Oshimura, A. P. Feinberg, and D. Gius CTCFL/BORIS Is a Methylation-Independent DNA-Binding Protein That Preferentially Binds to the Paternal H19 Differentially Methylated Region Cancer Res., July 15, 2008; 68(14): 5546 - 5551. [Abstract] [Full Text] [PDF]

				M. Monk, M. Hitchins, and S. Hawes Differential expression of the embryo/cancer gene ECSA(DPPA2), the cancer/testis gene BORIS and the pluripotency structural gene OCT4, in human preimplantation development Mol. Hum. Reprod., June 1, 2008; 14(6): 347 - 355. [Abstract] [Full Text] [PDF]

				A. Woloszynska-Read, P. Mhawech-Fauceglia, J. Yu, K. Odunsi, and A. R. Karpf Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3283 - 3290. [Abstract] [Full Text] [PDF]

				L. Sun, L. Huang, P. Nguyen, K. S. Bisht, G. Bar-Sela, A. S. Ho, C. M. Bradbury, W. Yu, H. Cui, S. Lee, et al. DNA Methyltransferase 1 and 3B Activate BAG-1 Expression via Recruitment of CTCFL/BORIS and Modulation of Promoter Histone Methylation Cancer Res., April 15, 2008; 68(8): 2726 - 2735. [Abstract] [Full Text] [PDF]

				S. Renaud, E. M. Pugacheva, M. D. Delgado, R. Braunschweig, Z. Abdullaev, D. Loukinov, J. Benhattar, and V. Lobanenkov Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors Nucleic Acids Res., December 18, 2007; 35(21): 7372 - 7388. [Abstract] [Full Text] [PDF]

				J. I. Risinger, G. V.R. Chandramouli, G. L. Maxwell, M. Custer, S. Pack, D. Loukinov, O. Aprelikova, T. Litzi, D. S. Schrump, S. K. Murphy, et al. Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression Clin. Cancer Res., March 15, 2007; 13(6): 1713 - 1719. [Abstract] [Full Text] [PDF]

				A. L. Hancock, K. W. Brown, K. Moorwood, H. Moon, C. Holmgren, S. H. Mardikar, A. R. Dallosso, E. Klenova, D. Loukinov, R. Ohlsson, et al. A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis Hum. Mol. Genet., February 1, 2007; 16(3): 343 - 354. [Abstract] [Full Text] [PDF]

				A. Ghochikyan, M. Mkrtichyan, D. Loukinov, G. Mamikonyan, S. D. Pack, N. Movsesyan, T. E. Ichim, D. H. Cribbs, V. V. Lobanenkov, and M. G. Agadjanyan Elicitation of T Cell Responses to Histologically Unrelated Tumors by Immunization with the Novel Cancer-Testis Antigen, Brother of the Regulator of Imprinted Sites J. Immunol., January 1, 2007; 178(1): 566 - 573. [Abstract] [Full Text] [PDF]

				M. Kim, D. Li, Y. Cui, K. Mueller, W. C. Chears, and J. DeJong Regulatory Factor Interactions and Somatic Silencing of the Germ Cell-specific ALF Gene J. Biol. Chem., November 10, 2006; 281(45): 34288 - 34298. [Abstract] [Full Text] [PDF]

				V. D'Arcy, Z. K. Abdullaev, N. Pore, F. Docquier, V. Torrano, I. Chernukhin, M. Smart, D. Farrar, M. Metodiev, N. Fernandez, et al. The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis. Clin. Cancer Res., October 15, 2006; 12(20): 5978 - 5986. [Abstract] [Full Text] [PDF]

				D. S. Schrump, M. R. Fischette, D. M. Nguyen, M. Zhao, X. Li, T. F. Kunst, A. Hancox, J. A. Hong, G. A. Chen, V. Pishchik, et al. Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura. Clin. Cancer Res., October 1, 2006; 12(19): 5777 - 5785. [Abstract] [Full Text] [PDF]

				B. Cadieux, T.-T. Ching, S. R. VandenBerg, and J. F. Costello Genome-wide Hypomethylation in Human Glioblastomas Associated with Specific Copy Number Alteration, Methylenetetrahydrofolate Reductase Allele Status, and Increased Proliferation. Cancer Res., September 1, 2006; 66(17): 8469 - 8476. [Abstract] [Full Text] [PDF]

				M. Monte, M. Simonatto, L. Y. Peche, D. R. Bublik, S. Gobessi, M. A. Pierotti, M. Rodolfo, and C. Schneider MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents PNAS, July 25, 2006; 103(30): 11160 - 11165. [Abstract] [Full Text] [PDF]

				Z. S. Guo, J. A. Hong, K. R. Irvine, G. A. Chen, P. J. Spiess, Y. Liu, G. Zeng, J. R. Wunderlich, D. M. Nguyen, N. P. Restifo, et al. De novo Induction of a Cancer/Testis Antigen by 5-Aza-2'-Deoxycytidine Augments Adoptive Immunotherapy in a Murine Tumor Model Cancer Res., January 15, 2006; 66(2): 1105 - 1113. [Abstract] [Full Text] [PDF]

				S. Vatolin, Z. Abdullaev, S. D. Pack, P. T. Flanagan, M. Custer, D. I. Loukinov, E. Pugacheva, J. A. Hong, H. Morse III, D. S. Schrump, et al. Conditional Expression of the CTCF-Paralogous Transcriptional Factor BORIS in Normal Cells Results in Demethylation and Derepression of MAGE-A1 and Reactivation of Other Cancer-Testis Genes Cancer Res., September 1, 2005; 65(17): 7751 - 7762. [Abstract] [Full Text] [PDF]